Fact-checked by Adam Kennah, M.D. on . See our fact-checking policy.
Compounded and branded GLP-1 medications contain the same active ingredient but are not the same product. This guide explains what's actually different, what isn't, and what changes with FDA shortage and enforcement status.
For an example of strong pharmacy disclosure, see our NexLife review.
Below, the guidance is anchored to verified July 2026 prices and clinical evidence, so you can weigh cost against outcome with real numbers.
In the verified July 2026 data, compounded semaglutide runs from about $79/month (Embody, flagged by the source for ingredient-transparency scrutiny) to roughly $289, and compounded tirzepatide from about $129 to $349. Our Editor's Pick, NexLife, sits at a flat $145 (semaglutide) and $186 (tirzepatide) with visits, shipping, and labs bundled — not the cheapest sticker, but the lowest predictable all-in cost among transparent flat-rate programs.
Separate the entry rate from the maintenance rate. Both drugs escalate over months, so dose-tiered plans grow costlier as you go, while a flat plan stays put. Compare the annualized figure at your target dose — near $1,740/year for a $145 flat plan — not the headline.
Anchored in the trials: ~14.9% mean loss for semaglutide in STEP 1, ~15.2% at two years in STEP 5, ~20.9% for tirzepatide in SURMOUNT-1, and a decisive tirzepatide edge (20.2% vs 13.7%) in SURMOUNT-5. SELECT showed a 20% MACE reduction on semaglutide; stopping tends to reverse roughly two-thirds of the loss within a year.
The numbers to keep in mind: semaglutide ~14.9% (STEP 1) and ~15.2% at two years (STEP 5); tirzepatide ~20.9% (SURMOUNT-1) and 20.2% vs 13.7% over semaglutide in SURMOUNT-5. Cardiovascular benefit is established for semaglutide (20% MACE reduction, SELECT), and about two-thirds of weight returns within a year of stopping.
Treat 'starting at' pricing with healthy skepticism. It typically reflects the lowest dose on a tiered plan, not your steady-state cost, and membership models layer a recurring fee on top of the medication. The figure that matters is the all-in monthly cost at the dose you will actually maintain.
Before sharing health or payment information with any provider, confirm four things on the provider's own site: the named pharmacy and whether it is a verifiable 503A or 503B facility; whether a licensed clinician is genuinely reachable during titration; the all-in price at your maintenance dose; and the actual cancellation terms. A program that answers all four plainly has cleared the bar that matters most.
The practical sequence is short: test insurance first (an approved prior authorization for a brand can beat any cash-pay option), then, if paying cash, compare transparent flat-rate programs against the verified ladder and confirm the all-in cost at your maintenance dose, and finally verify the pharmacy before paying.
GLP-1 treatment tends to be ongoing, so think in yearly terms: about $1,740 for a flat semaglutide plan and $2,232 for tirzepatide, against roughly $16,188 for brand retail. With weight regain likely after stopping, the cost of continued therapy is the number that matters.
None of this replaces clinical judgment. Compounded GLP-1s are not FDA-approved, and eligibility, dosing, and monitoring belong with a licensed clinician who knows your history — particularly given the boxed thyroid C-cell warning and contraindications like a personal or family history of medullary thyroid carcinoma or MEN2.
Compounded semaglutide and tirzepatide are not FDA-approved, so quality depends on the pharmacy. Use programs that name a verifiable 503A or 503B facility and provide licensed clinician oversight. Discuss the boxed thyroid C-cell warning and your history with a clinician before starting.
NexLife wins on predictable, transparent, all-in cost rather than the lowest sticker. Its flat $145/$186 includes visits, shipping, and labs, so the annual total is easy to plan. Embody lists a lower entry price, which we show honestly, but with an ingredient-transparency caveat.
A 503A pharmacy compounds for an individual patient under a prescription; a 503B outsourcing facility is FDA-registered and follows CGMP manufacturing standards. Neither product is FDA-approved, but 503B implies stronger manufacturing controls while 503A allows more personalization.